CA-IV Binder Conjugates for Blood-Brain Barrier Cargo Transport
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The blood-brain barrier (BBB) poses a significant challenge for delivering effective research tools and therapeutics to the central nervous system, as large molecules require invasive methods or receptor-mediated transcytosis, with limited understanding of transcytosis mechanisms and few validated targets.
Innovation Solution
Conjugates are developed using small molecule binders, such as FDA-approved drugs, that bind to carbonic anhydrase IV (CA-IV) to facilitate the delivery of therapeutic cargo across the BBB through receptor-mediated transcytosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If large molecules are delivered to the CNS, then therapeutic efficacy is improved, but invasive procedures or complex focused ultrasound methods are required
Solution Approach 1:
The patent uses CA-IV receptor as an intermediary to facilitate BBB crossing. The conjugate system comprises a CA-IV binder that specifically binds to CA-IV receptors on the BBB surface, enabling receptor-mediated transcytosis. This intermediary mechanism allows large therapeutic molecules to cross the BBB without requiring invasive procedures or complex focused ultrasound equipment, thereby resolving the contradiction between therapeutic efficacy and delivery method complexity.
2Reliability
If receptor-mediated transcytosis is used, then BBB crossing is achieved, but limited validated targets are available
Solution Approach 1:
The patent employs CA-IV as a universal BBB crossing target that can accommodate various therapeutic cargos. The conjugate system is designed with modular architecture where different therapeutic agents (large molecules, macromolecules) can be attached to the CA-IV binder. This multi-functional approach allows a single validated target (CA-IV) to serve multiple therapeutic purposes, thereby resolving the contradiction between reliable BBB crossing and limited target availability.
3Reliability
If transcytosis mechanisms are utilized, then BBB penetration is improved, but imperfect understanding of mechanisms limits rational design
Solution Approach 1:
The patent performs preliminary identification and validation of CA-IV as a BBB crossing target before developing the conjugate system. The inventors first identified CA-IV as a suitable target, then designed the conjugate based on this pre-validated target. This preliminary action of target validation simplifies the overall design process by providing a solid foundation, thereby resolving the contradiction between improved BBB penetration and reduced design complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These conjugates effectively deliver therapeutic cargo across the BBB, enhancing CNS potency by increasing permeability and overcoming the limitations of existing delivery methods.
Implementation Method 1
When provided to a cell expressing CA-IV as a surface protein, binding of the small molecule binder to the CA-IV protein mediates transcytosis of the therapeutic cargo across the BBB
Data Source
AI summary
The present invention provides small molecules that act as binders for the BBB-crossing through the receptor carbonic anhydrase IV (CA-IV).